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Expenditures of health care systems are increasing from year to year. Therefore, this
study aimed to estimate the difference in costs and benefits of innovative pharmaceu-
ticals launched 2000 onward compared to standard treatment on the national economy
of Switzerland in 2010. The approach and formula described in the pilot study by Tsiachris-
tas et al. (1), which analyzed the situation of welfare effects in the Netherlands, served
as a model for our own calculations. A literature search was performed to identify cost–
utility or cost-effectiveness studies of drugs launched 2000 onward compared to standard
treatment. All parameters required for the calculation of welfare effects were derived from
these analyses. The base-case threshold value of a quality-adjusted life year was set to
CHF 100,000. Overall, 31 drugs were included in the welfare calculations.The introduction
of innovative pharmaceuticals since 2000 onward to the Swiss market led to a poten-
tial welfare gain of about CHF 781 million in the year 2010. Univariate sensitivity analysis
showed that results were robust. Probably because of the higher benefits of new drugs on
health and quality of life compared to standard treatment, these drugs are worth the higher
costs. The literature search revealed that there is a lack of information about the effects
of innovative pharmaceuticals on the overall economy of Switzerland. Our study showed
that potential welfare gains in 2010 by introducing innovative pharmaceuticals to the Swiss
market were substantial. Considering costs and benefits of new drugs is important.
Keywords: welfare impact, cost-effectiveness, innovative drugs, economic evaluation, quality-adjusted life year
INTRODUCTION
The expenditures of most health care systems, e.g., the US and
several European health care systems (2) increased from year to
year, the same is true for the Swiss health care system (3). Hence,
there is an ongoing debate on how to stop or reduce the increase
in health care expenditures and keep the costs on an affordable
level. Compared to other countries, such as the US, Germany,
France, Austria, etc., Switzerland spent less on drugs in 2010
(Figure 1) (4). Although pharmaceutical expenditure in 2010
only accounted for 9.7% (CHF 6.05 billion) of total health care
expenditure in Switzerland (CHF 62.5 billion in 2010) (Figure 2)
and even decreased compared to the year 2009 (CHF 6.18 billion
or 10.1% of total health care expenditure) (5), health policy and
health decision-makers focused mainly on the price of novel and
existing medicines.
New or innovative medicines are often more expensive than
well-established drugs. This supports the common opinion that
the expenditures on drugs are too high and should be reduced.
For this reason, politicians and decision-makers often focus on the
price of a new drug when there are negotiations about introducing
a new drug to the Swiss market. Seldom is attention paid to the
fact that a new drug may have additional effects on the health state
or the quality of life of a patient compared to the standard drug,
i.e., the currently most prescribed drug for a given indication. For
example, the new drug costs more than the standard therapy. With-
out considering additional costs or benefits, we would conclude
that medical treatment of the patient with the new drug is more
expensive than treating the patient with the standard drug. Sup-
pose that the new drug reduces hospital length of stay or number of
physician visits compared to the standard therapy (6). This could
result in reduced resource use by the patient, which could save costs
in patients’ care (7). These additional benefits including external-
ities may outweigh the drug expenditures, and in the end we may
generate welfare gains due to the prescription of new drugs. There
is also evidence in international literature that health care expen-
diture positively effects on outcomes (8, 9) and increase in drug
spending leads to cost savings in other health care expenditures
and these savings often outweigh the spending (10–12). Others
argument that over the past 50 years, the majority of new products
(up to 90%) have provided only few benefits, but also considerable
harms that have added to national healthcare costs (13).
The timeliness of this topic is supported by a ruling of the Swiss
Federal Court of Justice in 2010 which stated that the treatment of
Morbus Pompe, which is a very rare disease, at CHF 500,000 per
year is too expensive given its only small health effects and that
health insurers are not required or forced to pay for such treat-
ments beyond the proposed threshold of CHF 100,000/QALY (14,
15). This is the first time that a formal and in this case legally bind-
ing cost-effectiveness threshold has been suggested in Switzerland.
To evaluate the health economic impact of a new pharmaceu-
tical, it is required to conduct a cost-effectiveness analysis that
considers not only the additional costs a new drug has compared
to an alternative, but also the additional benefits. Ideally, the
result of the cost-effectiveness analysis is presented as the ratio
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FIGURE 1 | Drug expenditures in percentage of total health care
expenditures of several countries compared to Switzerland.
FIGURE 2 | Swiss total health care expenditure in the year 2010.
of the differences of costs and QALYs (incremental cost–utility
ratio, ICUR) for the new drug compared to standard treatment,
because ICURs are not indication-specific and therefore, ICURs
of different diseases can be compared to each other.
The aim of this analysis was to show the importance of con-
sidering the costs of a new drug as well as its benefits from a
Swiss perspective and to evaluate the total potential annual wel-
fare impact due to the implementation of new drugs for the Swiss
economy in 2010.
MATERIALS AND METHODS
To the best of our knowledge, we are the first to assess the welfare
effects of innovative drugs in Switzerland. Another such evaluation
has already been performed in the Netherlands, which revealed
great potential welfare gains of introducing new pharmaceuticals
to the market (1). This evaluation and published report by Tsi-
achristas et al. (1) provided the methodological basis for our own
calculations. The aim of the exploratory study was to establish
knowledge in the welfare impact of innovative drugs introduced to
the Dutch market after 1997 to reflect a 10-year time horizon. The
authors mainly used pharmacoeconomic studies collected by the
Dutch Health Care Insurance Board (CVZ), the British National
Institute for Health and Clinical Excellence (NICE), and the Cana-
dian Agency for Drugs and Technologies in Health (CADTH).
A limited number of studies have been also collected from the
scientific literature and in total, 52 studies were included. The het-
erogeneous and foreign studies have been roughly adjusted to the
Dutch situation by using purchasing power parities (PPP) and the
deflator of the gross domestic product (GDP) as it is difficult to
adjust for varying cost calculation methods and other country-
specific aspects of a pharmacoeconomic evaluation. The welfare
gains amounted to C 1.7 billion based on a QALY valuation of
C 50,000. Further details of the methodology have already been
extensively described in the report (1).
Our approach was to estimate the welfare impact of a basket
of novel and innovative drugs in Switzerland for the year 2010,
which were launched 2000 onward. The parameters needed for
these calculations were derived from published literature.
LITERATURE SEARCH
A restrictive literature search based on the results of Tsiachris-
tas et al. (1) was conducted using the databases PubMed, the
Cost-Effectiveness Analyses (CEA) Registry, and data from the
Centre for Review and Dissemination (CRD). The search focused
on cost-effectiveness and cost–utility analyses, respectively. Refer-
ences from the beginning of the study up to 31st October 2010
were included. The included studies were restricted to English and
German language. The search focused on publications report-
ing CEA of new drugs launched 2000 onward in Switzerland.
Titles, abstracts, and finally full-texts of the articles found within
the search were screened to assess the eligibility of those cost-
effectiveness, respectively, cost–utility analyses. Studies that ful-
filled the following pre-defined inclusion criteria were considered:
• Costs were reported transparently and the reference price year
was presented
• The outcome measure was expressed in QALYs (preferred
outcome measure) or life years gained (LYG)
• At least, an incremental cost-effectiveness ratio (ICER, addi-
tional costs per additional effects, e.g., LYG, blood pressure
reduced by one unit, etc.) was reported (an ICUR was preferred)
• the time horizon was clearly stated.
For our analysis, it would have been more accurate to con-
sider only studies from a societal perspective (16). The societal
perspective includes not only the direct cost such as drug costs,
hospitalization costs, or costs for a physician visit, but also consid-
ers the indirect cost, e.g., the costs of productivity losses, work
absences, or informal care by family members. The literature
search identified only few studies from a societal perspective that
met the inclusion criteria. Hence, several studies from a health care
payer perspective had to be included in our analysis as well.
CALCULATING THE WELFARE IMPACT
The cost-effectiveness of a drug is not only influenced by its costs
and effects, but also by the society’s willingness-to-pay (WTP)
for a QALY or by the determined cost-effectiveness threshold of
a country. The cost-effectiveness threshold commonly used in
the US varies between US$ 50,000 and US$ 100,000 per QALY
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(17). NICE acceptable cost-effectiveness thresholds for the UK are
set at £ 20,000–30,000 per QALY (18). There is no official cost-
effectiveness threshold in Switzerland, but as mentioned above,
there was recently a discussion on this health topic initiated by a
ruling of the Federal Court of Justice in 2010 that one life year saved
is worth about CHF 100,000 (14, 15). Accordingly, we assumed that
in Switzerland the commonly used and accepted cost-effectiveness
threshold is CHF 100,000/QALY. However, in Switzerland this
threshold is still arguable and there will be further discussions
on this in the future.
To calculate the potential welfare impact of a new drug, it is
required to know the ICER, respectively, ICUR of this drug com-
pared to the standard treatment. Whereas the ICER is the ratio
between the additional costs of a drug compared to an alternative
treatment and the additional effects gained, respectively, effects
lost with the drug compared to an alternative (∆costs/∆effects),
the ICUR is the ratio between the additional costs of a drug com-
pared to an alternative treatment and the additional QALYs gained,
respectively, QALYs lost (∆costs/∆QALYs). One possibility to get
the ICERs/ICURs of innovative drugs would have been to per-
form several CEA of the respective drugs on our own, but as these
analyses have to be performed comprehensively and are therefore
very time-consuming, we decided to derive the ICERs/ICURs from
already published cost-effectiveness studies of the respective drugs.
The more patients benefit from a drug, the more attractive is
it not only from a healthcare point of view but also economically.
Hence, the number of patients possibly benefiting from the drug
was needed to calculate the welfare impact. The potential number
of users includes all patients who could possibly be treated with
a drug, but that is not always the same as actual users as not all
people affected by a disease get treated. Therefore, the best way
to assess the potential number of users is the estimated number
of customers from the manufacturer. Because the number of all
patients potentially benefiting of the respective drug was difficult
to obtain, the actual number of users had to be used in most cases.
Only for four different drugs, namely conjugated vaccine, iban-
dronate, atorvastatin, and memantine, the information about the
potential number of users was directly provided from the manu-
facturer. For risperdal and mimpara, the number of drug packages
sold in 2010 was provided by the pharmaceutical manufacturer
(IMS Health sales figures) and the number of actual users was
calculated indirectly based on the usual dosage prescribed (19).
For the other drugs, the number of actual users was provided by
the largest health insurance group in Switzerland, Helsana. These
numbers were not presented in the results due to confidentiality
reasons. The benefit from a drug also depends on the duration of
the effect, in this case approximately the time horizon (which was
either 1 year, as long as the duration of the treatment or longer)
used in the cost-effectiveness models, which was also retrieved
from the published literature.
Finally, the potential Swiss welfare impact in 2010 of a new
drug was calculated by using the following equation developed by
Tsiachristas et al. (1):
Welfare impact = [QALYvalue − cost/QALY]
× [∆ QALY/time horizon]× [number of users]
As explained in the original publication (1), QALYvalue in this
context meant QALY threshold and for cost/QALY, the ICER or
ICUR derived from published CEA was used. First, the ICER/ICUR
was subtracted from the QALY threshold mentioned above. Sec-
ond, the result was multiplied with the additional QALYs gained
or lost by the new drug divided by the time horizon to get the
additional QALYs gained or lost in 1 year and last, the result was
multiplied with the number of users.
Uncommonly, some new drugs do not only have better out-
comes, i.e., more LYs or QALYs are gained, but are also cheaper
than the alternative drugs. In this situation, where the result-
ing ICER/ICUR is negative it is called dominant and usually,
no ICER/ICUR is reported. But for the purpose of this study,
it was necessary to express all results as ICERs/ICURs, even if
they were negative. Hence, in these cases where the new drug had
better outcomes and was also cheaper than the standard treat-
ment, a negative ICER/ICUR was presented. This influenced the
equation in such a way, that in these cases the first part of the equa-
tion turned into QALYvalue+ cost/QALY, which led to a higher
potential welfare gain.
ADJUSTMENT OF THE DATA TO THE SWISS SITUATION IN 2010
Including only cost-effectiveness studies performed from a Swiss
perspective would have been preferred. Due to the fact that only
few cost-effectiveness studies have been conducted in a Swiss set-
ting, most cost-effectiveness studies included in our analysis were
studies from foreign countries. Accordingly, there was a need to
adjust the data to Switzerland before running the equation. The
ICERs/ICURs were first adjusted to the year 2010 of the original
country by using the deflator of GDP (20–25, 30). Then, PPPs were
used to convert the foreign ICER/ICUR results to Swiss francs (27).
UNIVARIABLE SENSITIVITY ANALYSIS
A univariate sensitivity analysis was conducted. Costs/QALY, i.e.,
the ICER or ICUR adjusted to Switzerland, the QALY effect itself,
and the time horizon were varied between 80 and 120% of the
original values (±20%). The formula shows that varying the QALY
effect and the number of users to the same extent would lead to the
same welfare impact. Therefore, the number of users was varied
between 50 and 150% of the original values (±50%). In addi-
tion, the calculation was performed using a QALY threshold of
CHF 50,000 reflecting also lower QALY thresholds such as in the
US and the UK and using a very high QALY threshold of CHF
150,000.
RESULTS
LITERATURE SEARCH
Our search identified 175 citations found in PubMed, CEA, and in
CRD. Titles and abstracts of all references were screened to identify
cost-effectiveness and cost–utility analyses. Full-texts were consid-
ered for the final inclusion of 31 studies (Table 1), of which 29 were
conducted in foreign settings and only two studies that also met
the inclusion criteria were conducted in a Swiss setting. There
was no need for adjustment of the data of these two studies (28,
29). Articles were mainly excluded because they did not report
an ICER/ICUR or they did not fulfill other pre-defined inclusion
criteria.
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Table 1 | Drugs included in the welfare basket.
Number Drug Brand Company
1 Bosentan
monohydrate (34)
Tracleer® Actelion
2 Peginterferon alfa 2a (35) Pegasys® Roche
3 Conjugated vaccine (36) Prevenar® Wyeth
4 Ezetimibe (37) Ezetrol® Merck Sharp &
Dohme
5 Sirolimus (38) Rapamune® Wyeth
6 Interferon beta-1a (39) Avonex® Biogen
7 Ibandronate (40) Bonviva® Roche
8 Rizatriptan (41) Maxalt® Merck Sharp &
Dohme
9 Linezolid (42) Zyvoxid® Pfizer
10 Rivastigmine (43) Exelon® Novartis
11 Rosiglitazone (44) Avandia® GlaxoSmithKline
12 Oseltamivir (45) Tamiflu® Roche
13 Clopidogrel (46) Plavix® Bristol-Myers Squibb
14 Memantine (47) Ebixa® H. Lundbeck
15 Risperidone (48) Risperdal® Janssen-Cilag
16 Atomoxetine (49) Strattera® Eli Lilly
17 Atorvastatin (50) Lipitor® Pfizer
18 Orlistat (51) Xenical® Roche
19 Natalizumab (52) Tysabri® Elan Pharma
20 Oxaliplatin (53) Eloxatin® Sanofi-Aventis
21 Rosuvastatin (54) Crestor® AstraZeneca
22 Trastuzumab (55) Herceptin® Roche
23 Cinacalcet (56) Mimpara® Amgen Europe
24 Sitagliptin (57) Januvia® Merck Sharp &
Dohme
25 Rimonabant (58) Acomplia® Sanofi-Aventis
26 Pimecrolimus (59) Elidel® Novartis
27 Human papillomavirus
vaccine (28)
Gardasil® Merck Sharp &
Dohme
28 Fulvestrant (60) Faslodex® AstraZeneca
29 Erlotinib (61) Tarceva® Roche
30 Eplerenone (62) Inspra® Pfizer
31 Raltegravir (29) Isentress® Merck Sharp &
Dohme
WELFARE IMPACT (BASE-CASE)
For every drug, the welfare impact was calculated separately
according to the formula described before. Generally, the results
of the individual drugs differed broadly (Table 2). There were
some drugs which did not generate much potential welfare gain
over 1 year compared to the standard treatment, e.g., peginterferon
alfa 2a (CHF 658,144), risperidone (CHF 996,206), rimonabant
(7,759), HPV vaccine (22,157), and others. Then, there were drugs
where the evidence of potential welfare gains with the introduction
of these drugs was much higher, e.g., bosentan monohydrate (CHF
10,717,090), clopidrogrel (CHF 257,359,200),pimecrolimus (CHF
54,412,070), etc. Nevertheless, each of the 31 reviewed drugs gen-
erated a positive result, meaning a clear welfare gain, except one of
the drugs. The introduction of cinacalcet (mimpara) to the Swiss
market resulted in a monetary loss compared to the standard treat-
ment. To obtain the total welfare impact for the Swiss economy
due to the introduction of innovative drugs to the Swiss market, all
results were summed up, which led to a total potential welfare gain
of CHF 781.39 million for the year 2010 (Table 2). This amounted
to about 0.0014% of the GDP in Switzerland in 2010 (30).
SENSITIVITY ANALYSIS
All results of the univariate sensitivity analysis showed the robust-
ness of the base-case findings, meaning that for every variation
of the input parameters, there was a potential welfare gain. The
most influential parameter was the QALY threshold followed by
the number of users (Figure 3), which were both varied by 50%.
When using a QALY threshold of CHF 50,000, the potential welfare
gain was only CHF 260.77 million, which was the lowest calculated.
In the sensitivity analysis, the potential welfare gain ranged from
CHF 260.77 million to CHF 1.30 billion (Figure 3).
DISCUSSION
To the best of our knowledge, this study is the first attempt to
calculate the welfare impact of innovative drugs in a Swiss setting.
Although the costs of the most innovative drugs often surpass the
costs of previous or existing pharmaceuticals, prescribing newer
drugs is still reasonable, at least in most cases due to more benefits.
Our base-case results showed that introducing innovative drugs to
the Swiss market led to potential welfare gains in 2010 accounting
for approximately CHF 781.39 million, which accounts for 13%
of total drug expenditure in 2010 in Switzerland (5). There was
only one drug included in our study that led to additional costs
per QALY gained compared to the standard treatment, i.e., which
decreased the potential welfare gained for the Swiss economy. The
sensitivity analysis showed that results were robust.
Some of the general limitations specific to the calculation
approach used in this study have already been discussed by the
original report published by Tsiachristas et al. (1). We are aware
that the formula created by the authors has not been utilized
widely; further validation is deemed necessary. Nevertheless, there
do not seem any a priori reasons to assume that the derived model
would not perform sufficiently adequate for our study question.
Other limitations include inconsistencies in the economic evalu-
ation, international differences in health care systems and health
determinants, limited data availability and lack of agreement about
the appropriate valuation of a QALY. Therefore, in the next section,
we will focus on limitations specific to our study.
LIMITATIONS OF THE STUDY
The main limitation of this study was probably the lack of Swiss-
specific data and when interpreting the welfare impact results,
it must be considered that in this study the obtained cost-
effectiveness data for Switzerland, i.e., the obtained ICERs/ICURs
for our calculations were in almost all the cases adjusted from
Frontiers in Public Health | Epidemiology May 2014 | Volume 2 | Article 48 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pavic et al. Welfare impacts of innovative drugs
Table 2 | Input parameters used for the welfare impact calculations.
Drug Cost/QALY
or LYG
ICER for
CH 2010
QALY effecta Time
horizon
(years)
Year Valuta Perspective Welfare
impact
(CHF)
Bosentan monohydrate
(Tracleer®)
55,927/LYG 63,562.2 3.87 LY 15 2004 AUD Health care payer 10,717,086
Peginterferon alfa 2a
(Pegasys®)
10,444/QALY 17,337.2 0.3 QALY 47.1 2005 GBP NHS 658,144
Conjugated vaccine
(Prevenar®)
28,156/LYG 49,606.73 0.0033 LY 10 2001 GBP Direct cost+ cost of work loss 1,026,706
Ezetimibe (Ezetrol®) 27,475/LYG 44,746.56 0.134 LY 24.1 2006 GBP Health care payer 6,234,995
Sirolimus (Rapamune®) −27,047/LYG −33,372.4 1.8 LY 20 2003 GBP NHS 18,005,274
Interferon beta-1a
(Avonex®)
44,789/MLY 49,449.91 1.21 MLY 12 2002 CAD Societal 1,778,900
Ibandronate (Bonviva®) −20,316/LYG −25,067.27 0.019 LY 1.19 2003 GBP NHS 3,935,835
Rizatriptan (Maxalt®) −6,625/QALY −7,185.73 0.00048 QALY 0.0027 2002 CAD Societal 268,926,615
Linezolid (Zyvoxid®) 29,945/QALY 34,533.36 6.73 QALY 9 2001 CAD Third-party payer 10,769,990
Rivastigmine (Exelon®) 7,249/QALY 7,561.74 0.0077 QALY 0.46 2004 CAD Societal 13,303,996
Rosiglitazone
(Avandia®)
5,137/QALY 9,147.21 0.1464 QALY 20 2000 GBP NHS 3,486,152
Oseltamivir (Tamiflu®) −6,182/QALY −5,226.96 0.0034 QALY 1 2006 USD Societal 3,630,309
Clopidogrel (Plavix®) 25,100/QALY 28,618.51 0.55 QALY 14.2 2002 USD Societal 257,359,176
Memantine (Ebixa®) −6,613/QALY −5,322.69 0.0276 QALY 2 2005 USD Societal 4,550,762
Risperidone
(Risperdal®)
39,890/QALY 40,619.47 0.0509 QALY 5 2006 USD Health care payer (Brazil) 996,206
Atomoxetine
(Strattera®)
15,224/QALY 25,688.75 0.046 QALY 1 2004 GBP NHS 4,430,139
Atorvastatin (Lipitor®) 43,667/QALY 59,662.96 0.033 QALY 4.8 2005 EUR Societal (Sweden) 55,463,430
Orlistat (Xenical®) 13,125/QALY 18,141.37 0.0304 QALY 1 2003 EUR Health care system (Sweden) 25,768,442
Natalizumab (Tysabri®) −11,265/QALY −12,799.14 0.34 QALY 20 2005 EUR Societal (Sweden) 1,961,690
Oxaliplatin (Eloxatin®) 4,805/QALY 8,082.99 0.68 QALY 50 2003 GBP Health care payer 3,725,213
Rosuvastatin (Crestor®) 36,548/QALY 49,426.78 0.08 QALY 23.5 2006 EUR Health care payer (Finland) 15,291,792
Trastuzumab
(Herceptin®)
35,975/QALY 49,153.24 0.262 QALY 25.4 2005 EUR Societal (Sweden) 1,216,275
Cinacalcet (Mimpara®) 61,890/QALY 104,433.05 0.34 QALY 24.1 2004 GBP Health care payer −59,101
Sitagliptin (Januvia®) 11,547/QALY 15,729.13 0.095 QALY 14.2 2006 EUR Health care payer (UK) 7,543,994
Rimonabant
(Acomplia®)
71,973/QALY 73,289.18 0.0581 QALY 5 2006 USD Third-party payer 7,759
Pimecrolimus (Elidel®) 35,000/QALY 38,642.23 0.03 QALY 0.5 2002 CAD Societal 54,412,070
HPV vaccine (Gardasil®) 26,005/QALY 26,885 0.020 QALY 70.55 2006 CHF Health care payer 22,157
Fulvestrant (Faslodex®) −33,571/QALY −40,140.15 0.021 QALY 10 2007 EUR Health care payer (Germany) 316,366
Erlotinib (Tarceva®) −212,700/QALY −184,240.96 0.01 QALY 2 2007 USD Health care payer 956,471
Eplerenone (Inspra®) 20,579/QALY 23,732.24 0.0676 QALY 12.8 2001 USD Health care payer 511,542
Raltegravir (Isentress®) 45,687/QALY 46,906 3.73 QALY 50 2007 CHF Health care payer 4,440,071
781,388,456
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; LYG, life year gained; NHS, National Health Service; MLY, monosymptomatic life year.
For reasons of confidentiality, the number of actual users is not declared.
aQALY effect means difference in quality-adjusted life years between treatment and comparator strategy.
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FIGURE 3 |Tornado diagram showing the results of the sensitivity analysis.
foreign cost-effectiveness data. As the costs of drugs, the life
expectancy, the national economy, and other factors affecting the
ICER/ICUR estimate differ between countries, the ICERs/ICURs
from another country might not be applicable to Switzerland
without further adjustments in addition to GDP and PPP con-
versions. For example, the comparative standard treatment used
in the country, the cost-effectiveness analysis was performed for
might differ from the standard treatment used in Switzerland. In
an economic analysis, the new treatment should always be com-
pared with the most relevant comparator in that setting or country.
Therefore, the ICER/ICUR of a new treatment in a foreign coun-
try compared to the county-specific relevant standard treatment
might not be exactly transferable to the Swiss setting. Because a
QALY is calculated by multiplying the utility weight of a given
state with the life years being in this state (31) and these utilities
are not the same among countries, the QALYs gained or lost with
the new drug compared to the standard treatment might differ
among countries. For these reasons, it would have been desirable
to use only Swiss data for our calculations to get a more reliable
estimate of the welfare impact of innovative drugs in Switzerland.
Another limitation of the study and its findings resulted from
the fact that many included studies were from a third-party payer
perspective and not from a societal perspective. Studies from a
third-party payer perspective only include direct costs, such as
hospitalization costs, drug costs, physician costs, etc. To assess
the welfare impact of innovative drugs, also indirect costs, e.g.,
productivity losses, work absences, informal care by family mem-
bers, etc., should be considered as these can have a substantial
effect on the resulting ICER/ICUR of a new drug compared to
standard treatment. Because the majority of the included cost-
effectiveness studies were from a third-party payer perspective and
those studies from a societal perspective did not always met the
other pre-defined inclusion criteria, we decided to also include
studies from a third-party payer perspective. Otherwise, our bas-
ket of innovative drugs available to calculate the welfare impact in
Switzerland in 2010 would have been much smaller and might not
have been representative of innovative drugs in Switzerland. Bear-
ing in mind that we only included 31 drugs in our calculations and
in Switzerland approximately 700 new drugs were registered since
2000 onward (32), the inclusion of studies was very restrictive and
the potential welfare gain could even be higher.
A further limitation is the number of users derived for our cal-
culations. Very often there was not much information available
about the potential users and therefore, we had to use the num-
ber of actual users in the year 2010 as an approximate estimate
for the number of potential users (except for Conjugated vaccine,
ibandronate, atorvastatin, and memantine), which is not always
consistent. Furthermore, it was not possible to obtain the number
of actual users directly from the manufacturers for every drug. For
risperidone and cinacalcet, an estimate had to be made based on
data from the number of sold packages in Switzerland (informa-
tion was provided from the manufactures who had this number
from IMS Health sales figures) and the standard dose for the spe-
cific drug (19). All other numbers of actual users were provided by
the Helsana Group, the largest health insurer in Switzerland. With
1.8 million Swiss people insured (33), we think that Helsana is
representative enough to estimate the actual users in Switzerland.
As actual users might differ from potential users and the welfare
impact calculations depend on the number of users, we were aware
that the result could differ substantially.
It must be mentioned that not all of the cost-effectiveness stud-
ies measured the clinical effects expressed in QALYs, which was
the preferred outcome measure. Instead, for five drugs (bosentan
monohydrate, conjugated vaccine, ezetimibe, sirolimus, and iban-
dronate) the effect was measured in LYG which does not take into
account the quality of life during the additional LYG by the new
drug. The equivalent QALY estimate could be much lower, e.g., the
patient gained one life year by the new treatment but the quality of
life was as bad as 0.2 and therefore, the new drug would only have
a benefit of 0.2 QALYs gained instead of one LYG meaning that
the calculated welfare impact of these five drugs might be lower
when calculated by using QALYs. The same applied for the welfare
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impact calculations of interferon beta-1a. The authors of this study
used monosymptomatic life years (MLY) as the measure of effect.
Some drugs included in our study (bosentan monohy-
drate, peginterferon 2a, ibandronate, risperidone, oxaliplatin,
trastuzumab, cinacalcet, and erlotinib) are used for more than
one indication. In all cases, the cost-effectiveness study was con-
ducted for one indication only. The information about volume of
users we got from the manufacturers of the drug or Helsana, or we
calculated based on the number of sold packages made no differ-
ence between the diverse indications. But it is very likely that the
QALY gain of the drug is not the same for every indication. For
these particular drugs, we might have overestimated the welfare
impact by using the total number of volume users independent
from indication and the QALY effect of the drug measured for
only one indication.
Nevertheless, our calculations were conservative and included
only a small portion of the total number of innovative drugs
launched 2000 onward in Switzerland. The potential welfare gain
generated by the introduction of new drugs in Switzerland in 2010
was substantial and the sensitivity analysis showed that using a
lower QALY threshold of CHF 50,000 also led to a potential wel-
fare gain in 2010. Together with the fact that the prices of many
new drugs in Switzerland have decreased, the total potential wel-
fare gain might be even greater. As one drug (Mimpara) showed
negative welfare effects, we cannot generally conclude that there is
a positive welfare effect of new drugs compared to standard treat-
ment. But this finding should effect that health decision makers
do not only discuss the price of a new pharmaceutical but also
its benefit, ideally expressed in QALYs. For this purpose, there is
an urgent need for performing CEA of novel pharmaceuticals, if
possible prior to the introduction to the market.
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